摘要
Objective To investigate the therapeutic effects of the combination of rosiglitazone, which is peroxisome proliferators-activated receptorγ(PPARγ) ligands used to treat type 2 diabetes mellitus, and aminosalicylate on mildly or moderately active ulcerative colitis and on relevant cytokine expressions. Methods According to
